BHC
Bausch Health Companies Inc

41,908
Mkt Cap
$2.13B
Volume
2.24M
52W High
$8.69
52W Low
$4.25
PE Ratio
5.92
BHC Fundamentals
Price
$5.74
Prev Close
$5.59
Open
$5.59
50D MA
$6.79
Beta
1.17
Avg. Volume
2.67M
EPS (Annual)
-$0.125
P/B
-3.76
Rev/Employee
$464,975.84
Loading...
Loading...
News
all
press releases
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down
Bausch Health shares slide after late-stage RED-C trials for rifaximin SSD fail, derailing plans to expand Xifaxan's cirrhosis-related use.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC)
Bausch (BHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·6d ago
News Placeholder
BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’
The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.
Stocktwits·9d ago
News Placeholder
Bausch Health Companies (TSE:BHC) Shares Down 8.8% - What's Next?
Bausch Health Companies (TSE:BHC) Trading Down 8.8% - Should You Sell...
MarketBeat·9d ago
News Placeholder
Bausch Health Companies Becomes Oversold (BHC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Nasdaq News: Markets·9d ago
News Placeholder
Bausch Health Cos (NYSE:BHC) Shares Gap Down - Should You Sell?
Bausch Health Cos (NYSE:BHC) Shares Gap Down - Time to Sell...
MarketBeat·9d ago
News Placeholder
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials Bausch Health Provides Update on RED-C Phase 3 Clinical Trials PR Newswire LAVAL, QC, Jan. 23, 2026 LAVAL, QC, Jan. 23, 2026...
PR Newswire·10d ago
News Placeholder
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026 Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026 PR Newswire LAVAL...
PR Newswire·12d ago
News Placeholder
Bausch Health Cos Inc. (NYSE:BHC) Sees Significant Decrease in Short Interest
Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling...
MarketBeat·14d ago
News Placeholder
Wall Street Zen Downgrades Bausch Health Cos (NYSE:BHC) to Buy
Wall Street Zen lowered shares of Bausch Health Cos from a "strong-buy" rating to a "buy" rating in a research note on Saturday...
MarketBeat·16d ago
<
1
2
...
>

Latest BHC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.